Bristol Myers Squibb Company $BMY Holdings Trimmed by AEGON ASSET MANAGEMENT UK Plc

AEGON ASSET MANAGEMENT UK Plc trimmed its holdings in shares of Bristol Myers Squibb Company (NYSE:BMY - Free Report) by 6.3% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 594,983 shares of the biopharmaceutical company's stock after selling 40,269 shares during the period. AEGON ASSET MANAGEMENT UK Plc's holdings in Bristol Myers Squibb were worth $37,127,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also recently bought and sold shares of BMY. BlackRock Inc. lifted its position in shares of Bristol Myers Squibb by 5.1% in the second quarter. BlackRock Inc. now owns 180,384,994 shares of the biopharmaceutical company's stock worth $10,393,783,000 after buying an additional 8,702,106 shares during the last quarter. State Street Corp boosted its stake in shares of Bristol Myers Squibb by 7.3% during the 2nd quarter. State Street Corp now owns 105,757,638 shares of the biopharmaceutical company's stock worth $6,093,755,000 after acquiring an additional 7,192,724 shares in the last quarter. Primecap Management Co. CA acquired a new position in shares of Bristol Myers Squibb during the 2nd quarter valued at about $1,436,115,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its holdings in shares of Bristol Myers Squibb by 0.5% during the 2nd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 22,839,010 shares of the biopharmaceutical company's stock valued at $1,315,984,000 after acquiring an additional 119,690 shares during the last quarter. Finally, Dimensional Fund Advisors LP raised its stake in shares of Bristol Myers Squibb by 2.9% in the 1st quarter. Dimensional Fund Advisors LP now owns 18,762,589 shares of the biopharmaceutical company's stock valued at $1,137,847,000 after acquiring an additional 520,330 shares in the last quarter. 76.41% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several research analysts recently commented on the stock. Raymond James Financial assumed coverage on shares of Bristol Myers Squibb in a report on Wednesday, August 5th. They issued a "strong-buy" rating on the stock. Wells Fargo & Company lowered their price target on Bristol Myers Squibb from $65.00 to $60.00 and set an "equal weight" rating on the stock in a research report on Tuesday, October 13th. BMO Capital Markets reiterated a "market perform" rating on shares of Bristol Myers Squibb in a research note on Monday, July 27th. Piper Sandler cut their price objective on Bristol Myers Squibb from $82.00 to $78.00 and set an "overweight" rating for the company in a research report on Monday, October 26th. Finally, Zacks Research downgraded Bristol Myers Squibb from a "strong-buy" rating to a "hold" rating in a research note on Thursday, October 22nd. Two analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, sixteen have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company has an average rating of "Hold" and a consensus price target of $65.46.

Insider Buying and Selling

In other news, Director Julia A. Haller sold 3,800 shares of the firm's stock in a transaction that occurred on Thursday, November 5th. The stock was sold at an average price of $63.31, for a total value of $240,578.00. Following the completion of the sale, the director directly owned 30,279 shares of the company's stock, valued at $1,916,963.49. This trade represents a 11.15% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, SVP Phil M. Holzer sold 500 shares of Bristol Myers Squibb stock in a transaction that occurred on Tuesday, August 25th. The stock was sold at an average price of $67.50, for a total value of $33,750.00. Following the transaction, the senior vice president owned 16,862 shares of the company's stock, valued at $1,138,185. This represents a 2.88% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. 0.05% of the stock is owned by insiders.

Bristol Myers Squibb Stock Up 0.0%

Shares of BMY opened at $62.16 on Tuesday. The company has a debt-to-equity ratio of 1.79, a quick ratio of 1.44 and a current ratio of 1.59. Bristol Myers Squibb Company has a 52 week low of $45.26 and a 52 week high of $68.64. The firm has a market capitalization of $127.06 billion, a price-to-earnings ratio of 13.78, a PEG ratio of 0.33 and a beta of 0.20. The business's fifty day moving average price is $62.25 and its two-hundred day moving average price is $60.15.

Bristol Myers Squibb (NYSE:BMY - Get Free Report) last announced its quarterly earnings results on Thursday, October 29th. The biopharmaceutical company reported $1.35 EPS for the quarter, beating analysts' consensus estimates of $1.10 by $0.25. The company had revenue of $13.07 billion during the quarter, compared to analysts' expectations of $12.72 billion. Bristol Myers Squibb had a return on equity of 60.48% and a net margin of 18.47%. Bristol Myers Squibb's revenue was up 6.9% on a year-over-year basis. During the same period in the prior year, the business posted $1.63 EPS. On average, analysts predict that Bristol Myers Squibb Company will post 6.45 earnings per share for the current year.

Bristol Myers Squibb Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Monday, November 2nd. Investors of record on Friday, October 2nd were issued a dividend of $0.63 per share. The ex-dividend date was Friday, October 2nd. This represents a $2.52 dividend on an annualized basis and a yield of 4.1%. Bristol Myers Squibb's dividend payout ratio (DPR) is presently 55.88%.

Bristol Myers Squibb Company Profile

Bristol Myers Squibb is a global biopharmaceutical company that discovers, develops, manufactures and markets medicines. Its research and commercial activities focus on serious diseases, particularly cancer, blood disorders, immune-mediated conditions and cardiovascular disease.

The company's medicines include Opdivo and Yervoy for cancer, Eliquis for preventing and treating blood clots, and Orencia for certain autoimmune conditions. Its portfolio also includes treatments for hematologic diseases and other serious illnesses.

Bristol Myers Squibb was formed in 1989 through the merger of Bristol-Myers, founded in 1887, and the E.

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol Myers Squibb Company (NYSE:BMY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.